{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T18:54:46Z","timestamp":1769799286207,"version":"3.49.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Emerging preclinical evidence challenges the long-standing assumption that Interleukin-1\u03b2 (IL-1\u03b2) uniformly promotes non\u2013small cell lung cancer (NSCLC). We show that, in the context of chemo-immunotherapy, IL-1\u03b2 enhances anti-tumor immunity by inducing tumor-cell CXCL10 expression and recruiting CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, thereby sensitizing \u201ccold\u201d tumors to treatment. These findings contrast sharply with the failure of multiple CANOPY trials targeting IL-1\u03b2, suggesting that blockade may be effective only in prevention or early carcinogenesis. Instead, controlled IL-1\u03b2 activation, guided by biomarkers and combined with chemotherapy plus PD-1 blockade, may represent a promising strategy to overcome resistance in established NSCLC.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1773253","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:41:28Z","timestamp":1769755288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The promise of IL-1\u03b2 modulation in NSCLC clinical context"],"prefix":"10.3389","volume":"17","author":[{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"R\u00e9b\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10244","DOI":"10.1038\/s41467-025-64839-4","article-title":"Cancer cell-derived IL-1\u03b2 reverses chemo-immunotherapy resistance in non-small cell lung cancer","volume":"16","author":"Perrichet","year":"2025","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0960","article-title":"IL-1\u03b2-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-1099-5","article-title":"Targeting the IL-1\u03b2\/EHD1\/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC","volume":"39","author":"Huang","year":"2020","journal-title":"Oncogene"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157788","article-title":"Targeting IL-1\u03b2 as an immunopreventive and therapeutic modality for K-ras\u2013mutant lung cancer","volume":"7","author":"Yuan","year":"2022","journal-title":"JCI Insight"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/JCO.23.00980","article-title":"Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non\u2013small-cell lung cancer: results from the CANOPY-1 trial","volume":"42","author":"Tan","year":"2024","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as adjuvant therapy in patients with completely resected non-small-cell lung cancer: results from the CANOPY-A double-blind, randomized clinical trial","volume":"42","author":"Garon","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107451","article-title":"Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial","volume":"189","author":"Paz-Ares","year":"2024","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100859","article-title":"CANOPY-N: A phase 2 study of canakinumab or pembrolizumab, alone or in combination, as neoadjuvant therapy in patients with resectable, stage IB\u2013IIIA NSCLC","volume":"6","author":"Lee","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.10.004","article-title":"Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions","volume":"44","author":"Peng","year":"2025","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.102002","article-title":"Interleukin-1\u03b2 and cancer immune response","volume":"80","author":"R\u00e9b\u00e9","year":"2025","journal-title":"Semin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1773253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:41:32Z","timestamp":1769755292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1773253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2026.1773253"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1773253","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1773253"}}